MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/13596535251323728

Медицинская библиотека · Antiviral therapy · 2025

Nirmatrelvir treatment duration and frequency of COVID-19 rebound.

Sudeep Nathan, Kojima Noah, Klausner Jeffrey D

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Nirmatrelvir has been shown to reduce morbidity and mortality associated with COVID-19. However, it is underutilized due to concerns regarding COVID-19 symptom rebound following nirmatrelvir's standard 5-day course. This study aims to identify and evaluate a nirmatrelvir dosage regimen that lowers symptom rebound.

METHODS

Based on nirmatrelvir pharmacokinetics, we propose a novel 8-day regimen: two doses twice-daily followed by six doses once-daily to reduce rebound frequency. We then carried out a retrospective case series study of clinical outcomes among our patients to investigate their frequency of COVID-19 symptom rebound following nirmatrelvir usage.

RESULTS

Among the 58 prescribed case patients, 49 filled and initiated the prescription. Of those 49 patients, four took the medication for fewer than 5 days, 24 for 5 days (standard regimen), and 21 for 7 or 8 days (extended regimen). Among 5-day treatment cases (n = 24), 8 (33%) experienced clinical rebound, whereas among the 7-day or 8-day treatment cases (n = 21), 2 (9.5%) experienced rebound.

CONCLUSIONS

These findings suggest that a longer nirmatrelvir/ritonavir course might reduce rebound symptoms compared to the standard 5-day regimen.

Для цитирования: Sudeep Nathan, Kojima Noah, Klausner Jeffrey D. Nirmatrelvir treatment duration and frequency of COVID-19 rebound.. Antiviral therapy. 2025. DOI: 10.1177/13596535251323728.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.